EX-99.2 4 y90840exv99w2.txt CERTAIN SUPPLEMENTAL INFORMATION Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES THIRD QUARTER 2003 NET PRODUCT SALES DETAIL
3Q '03 vs. 3Q '02 ---------------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ------- ----- ---- ----- ---- ----- ------ AGGRASTAT -3% 26 -43% 7 34% 18 ARCOXIA * 19 -- -- * 19 CANCIDAS * 77 * 48 * 29 COZAAR / HYZAAR 13% 622 3% 229 21% 393 CRIXIVAN/STOCRIN -2% 64 -20% 15 6% 49 EMEND * 4 * 4 * 0 FOSAMAX 52% 687 55% 411 48% 276 INVANZ * 11 * 9 * 3 MAXALT 32% 101 31% 75 38% 27 PRIMAXIN 15% 171 32% 58 7% 112 PRINIVIL / PRINZIDE -65% 26 -76% 13 -25% 12 PROPECIA 10% 59 9% 27 11% 32 PROSCAR -18% 126 -45% 47 16% 80 SINGULAIR 80% 616 98% 473 39% 143 TIMOPTIC/TIMOPTIC XE -6% 39 18% 5 -8% 34 TRUSOPT/COSOPT 13% 120 13% 50 13% 70 VASOTEC / VASERETIC -1% 186 64% (2) -3% 188 VIOXX -32% 510 -52% 258 21% 252 ZOCOR -2% 1,405 15% 994 -29% 411 HEPATITIS VACCINES 6% 71 16% 62 -34% 9 VIRAL VACCINES 11% 160 8% 149 87% 10 OTHER VACCINES 5% 81 -1% 66 46% 15
* > 100% N/M - Not Meaningful TOTAL SALES: VOLUME, PRICE, EXCHANGE
3Q '03 % CHG. VOL PX FX TOTAL PHARMACEUTICAL SALES 5,762 6% 3 1 2 ----- -- -- -- -- U.S. 3,514 7% 5 2 0 Foreign 2,248 6% 1 -1 6
Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES NINE MONTHS YEAR TO DATE 2003 NET PRODUCT SALES DETAIL
SEPTEMBER YTD '03 vs. SEPTEMBER YTD '02 ----------------------------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ------- ----- - ----- - ----- - AGGRASTAT -5% 74 -52% 17 33% 58 ARCOXIA * 46 - - * 46 CANCIDAS * 185 * 110 * 75 COZAAR / HYZAAR 20% 1,796 6% 662 30% 1,133 CRIXIVAN/STOCRIN 6% 229 3% 78 7% 151 EMEND * 19 * 19 * 0 FOSAMAX 31% 2,026 16% 1,239 63% 788 INVANZ * 26 * 20 * 5 MAXALT 15% 230 8% 159 35% 71 PRIMAXIN 17% 480 32% 153 11% 327 PRINIVIL / PRINZIDE -78% 100 -86% 57 -17% 43 PROPECIA 14% 175 17% 84 12% 91 PROSCAR 14% 438 7% 196 20% 242 SINGULAIR 53% 1,502 55% 1,071 48% 431 TIMOPTIC/TIMOPTIC XE -6% 117 -37% 12 0% 105 TRUSOPT/COSOPT 13% 348 9% 145 17% 202 VASOTEC / VASERETIC -4% 554 * (10) -2% 565 VIOXX -14% 1,818 -28% 1,099 22% 719 ZOCOR 2% 3,798 12% 2,381 -12% 1,416 HEPATITIS VACCINES 10% 188 10% 159 13% 29 VIRAL VACCINES -4% 411 -7% 383 * 28 OTHER VACCINES 14% 189 10% 151 32% 38
* > 100% N/M - Not Meaningful TOTAL SALES: VOLUME, PRICE, EXCHANGE
YTD '03 % CHG. VOL PX FX TOTAL PHARMACEUTICAL SALES 16,859 10% 5 1 4 ------ --- -- -- -- U.S. 10,170 7% 4 3 0 Foreign 6,689 14% 5 -1 10
Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES THIRD QUARTER 2003 OTHER (INCOME)/EXPENSE, NET
3Q '03 3Q '02 YTD 2003 YTD 2002 ------ ------ -------- -------- INTEREST INCOME $(66.9) $(106.5) $(236.5) $(307.8) INTEREST EXPENSE 81.1 99.9 270.9 292.5 EXCHANGE (GAINS)/LOSSES (1.7) 8.3 (25.1) 10.9 MINORITY INTERESTS 39.1 59.1 131.5 169.7 AMORTIZATION OF INTANGIBLES 36.1 29.9 104.3 89.8 Other, net (38.9) (43.9) (270.2) (123.1) ------ ------ ------ ------ TOTAL $ 48.8 $ 46.8 $(25.1) $132.0
JOINT VENTURE SALES DETAIL All sales reported here are end-market JV sales, presented on a "NET" basis.
MERIAL 3Q '03 3Q '02 YTD 2003 YTD 2002 ------ ------ -------- -------- IVOMEC, HEARTGARD, other avermectins $ 141 $ 129 $ 352 $ 349 FRONTLINE 183 147 485 409 Biologicals 106 91 306 274 Other Animal Health 55 43 152 135 Poultry Genetics 38 38 113 117 ------- ------- ------- ------- TOTAL MERIAL SALES $ 523 $ 448 $ 1,408 $ 1,284
AVENTIS PASTEUR-MSD 3Q '03 3Q '02 YTD 2003 YTD 2002 ------ ------ -------- -------- HEPATITIS VACCINES $ 18 $ 19 $ 55 $ 49 VIRAL VACCINES 16 10 40 26 Other Vaccines 200 177 404 327 ------- ------- ------- ------- TOTAL AP-MSD SALES $ 234 $ 206 $ 499 $ 402
MERCK / SCHERING-PLOUGH COLLABORATION 3Q '03 3Q '02 YTD 2003 YTD 2002 ------ ------ -------- -------- Zetia (Worldwide) $ 136 $ - $ 305 $ - TOTAL $ 136 $ - $ 305 $ -